The drug combination of Lynparza (olaparib), Zytiga (abiraterone) and prednisone led to better progression-free survival outcomes and responses compared to ...

The combination of Cabometyx (cabozantinib) plus Tecentriq (atezolizumab) outperformed novel hormonal therapy (NHT) when it came to progression-free ...

Researchers have determined the maximum-tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative ...

A type of novel CD NK therapy may be a promising treatment for some patients with certain blood cancers.CD19-targeting cord blood-derived chimeric antigen ...

When I first heard I had an incurable, but indolent cancer, my world exploded. I couldn’t even wrap my head around it, as they say. It took time to process ...

The challenges Despite justifiable optimism, we still have to overcome some big hurdles before immunotherapy starts to show the same benefits we’ve seen ...

Often, receiving a cancer diagnosis can require a crash course in oncology that few patients ever expected to take.For colorectal cancer specialist Dr. ...

Reducing harmful side effects One such trial is TORPEdO, led by Dr David Thompson at The Christie Hospital in Manchester. Supported by the Taylor ...

An expert explains how immunotherapy works. The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) ...

Since our researchers helped discover BRCA genes in the 1990s, doctors have been able to use treatments like talazoparib to target common features of ...

Why do you support Cancer Research UK? We started to support cancer research before either of our families were touched directly by cancer, but we ...

Circulating tumor DNA (ctDNA), describes the cancer fragments that can be detected in a patient’s bloodstream. While the role of ctDNA has not definitively ...